Pharmacology of moclobemide
- PMID: 8313402
Pharmacology of moclobemide
Abstract
Moclobemide is a reversible inhibitor of monoamine oxidase (MAO) with clear preference for the A type (so-called RIMA). The enzyme inhibition shows complex kinetics, and the molecular mechanism of interaction with the enzyme is not yet clear. Moclobemide increases the extracellular concentration of the monoamines in rat brain and decreases the level of their metabolites. Neither a loss nor a cumulation of activity has been observed after chronic treatment. Reversibility of MAO-A inhibition was demonstrated in vitro as well as in vivo. In various animal behavioral models, in particular in a novel model of stress-induced anhedonia, moclobemide was as effective as standard antidepressants. Moclobemide improves cognitive functions that are impaired in experimental situations. A neuroprotective action is seen in rats subjected to transient global ischemia/-hypoxia. Moclobemide lacks anticholinergic and other effects and only slightly increases the pressor effect of orally administered tyramine. Possible links between MAO-A inhibition and the various effects of moclobemide on brain function are discussed.
Similar articles
-
Some basic aspects of reversible inhibitors of monoamine oxidase-A.Acta Psychiatr Scand Suppl. 1990;360:7-12. doi: 10.1111/j.1600-0447.1990.tb05317.x. Acta Psychiatr Scand Suppl. 1990. PMID: 2248079
-
Biochemistry and pharmacology of moclobemide, a prototype RIMA.Psychopharmacology (Berl). 1992;106 Suppl:S6-14. doi: 10.1007/BF02246225. Psychopharmacology (Berl). 1992. PMID: 1546143 Review.
-
Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.J Pharmacol Exp Ther. 1989 Jan;248(1):391-9. J Pharmacol Exp Ther. 1989. PMID: 2913284
-
Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.J Pharmacol Exp Ther. 1989 Jan;248(1):400-14. J Pharmacol Exp Ther. 1989. PMID: 2783611
-
Hypotensive action and weak potentiation of tyramine effect by moclobemide in rats.Acta Psychiatr Scand Suppl. 1990;360:106-7. doi: 10.1111/j.1600-0447.1990.tb05350.x. Acta Psychiatr Scand Suppl. 1990. PMID: 2248060 Review.
Cited by
-
Rasagiline is neuroprotective in an experimental model of brain ischemia in the rat.J Neural Transm (Vienna). 2007;114(5):595-605. doi: 10.1007/s00702-006-0612-5. Epub 2006 Dec 21. J Neural Transm (Vienna). 2007. PMID: 17177075
-
Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases.J Neural Transm (Vienna). 2018 Nov;125(11):1719-1733. doi: 10.1007/s00702-018-1942-9. Epub 2018 Oct 19. J Neural Transm (Vienna). 2018. PMID: 30341696 Review.
-
Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19.Br J Clin Pharmacol. 2002 Apr;53(4):393-7. doi: 10.1046/j.1365-2125.2002.01366.x. Br J Clin Pharmacol. 2002. PMID: 11966672 Free PMC article. Clinical Trial.
-
Treatment of Depression in the Patient with Parkinson's Disease.Clin Geriatr. 1998 Oct;6(11):34-46. Clin Geriatr. 1998. PMID: 28529443 Free PMC article. No abstract available.
-
The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers.Br J Clin Pharmacol. 1999 Aug;48(2):190-6. doi: 10.1046/j.1365-2125.1999.00011.x. Br J Clin Pharmacol. 1999. PMID: 10417495 Free PMC article. Clinical Trial.